Autopsy report · NCT04918511

A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma

“Sponsor made the decision to terminate the COAST study to refocus the OPD5 clinical program.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Oncopeptides AB

Sponsor type

Industry

Conditions

Relapse Multiple Myeloma; Multiple Myeloma

Interventions

OPD5

Participants

0

Sites

3

Countries

Czechia

Trials that died the same way

• Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)
  “The Sponsor chose to terminate this study for commercial reasons.” (66% match in meaning)
• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (65% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (65% match in meaning)
• Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
  “Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.” (65% match in meaning)
• A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
  “The study was terminated by sponsor for reasons of adjusted clinical development strategy.” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.